Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: JOHN W. who wrote (1906)	9/29/1997 8:14:00 PM
From: Randy Schmid	of 6136

Just because you're paranoid doesn't mean they're not out to get you. I say we all blitz Cramer with e-mail asking where his reporter's integrity is when AGPH reports its findings on Viracept. AGPH's press release about 1 yr potency against HIV was steadfastly ignored. Thestreet.com's reporter seemed quite well connected to the short interest issue. If we're gonna blitz, we need to do it before AGPH presents. Some of the other articles weren't very complimentary of Crix bid dosing and the soft gel Saquinivir reports. The same author reported that there was no diminishment of kidney stones in the bid Crix dosing, and that Saq wasn't even bioavailable enough to do much good with AIDs, so that the gel was a much needed drawing nearer to even ground. I hope there's a broadside back on this whole thing, and that it isn't just AGPH investor relations with some standard corporate speak rebuttal. That's not good enough for reversal of fortune. street.com set the agenda, unfortunately, and AGPH needs to set a new agenda in the investment arena, or it'll always be getting blindsided with people who want a piece of the new kid in town. Frustratingly, Randy

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next